Re Contract

Deltex Medical Group PLC
27 May 2005



DELTEX MEDICAL GROUP PLC
27 MAY 2005


                  Deltex Medical Group plc ('Deltex Medical' / 'Company')

                 Deltex Medical Secures Another Major NHS Order for CardioQ



Deltex Medical Group plc ('Deltex Medical' or 'Company'), the AIM listed
haemodynamic monitoring company today announces the receipt of a further major
order from an NHS Trust to implement the Company's CardioQ(TM) system as a
standard of care in moderate and major risk surgery.

Worcestershire Royal Hospital, which is part of Worcestershire Acute Hospitals
NHS Trust, has successfully concluded an audit using the CardioQ on patients
undergoing a range of moderate and major risk surgical procedures. The outcome
of this audit demonstrated to the satisfaction of both the Trust managers and
doctors, that a significant reduction in average length of stay across these
surgical procedures had been achieved over the course of the exercise.
Consequently, the hospital has purchased a total of 6 CardioQ monitors to be
installed in operating theatres within Worcestershire Royal Hospital and are now
looking to implement this technology across the rest of the Trust.

Andy Hill, Deltex Medical's Chief Executive, said: 'It's very pleasing to see
the results of our marketing efforts with NHS hospitals. This major order from
Worcestershire Royal Hospital and other recent placements indicate that we are
starting to see the CardioQ gather some real momentum in the marketplace. At the
same time, our discussions continue with other NHS Trusts regarding
implementation of the CardioQ and we expect to announce further orders as these
discussions progress.'
For further information, please contact:-


Deltex Medical Group plc                               01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics                                     0207 831 3113
David Yates
Lucy Briggs




Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQ works in a wide range of surgical procedures



  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.



Deltex Medical is developing a wholly non-invasive monitoring solution,
SupraQ(TM), that will enable medical practitioners to determine a patient's
haemodynamic status and take appropriate action in any setting; at the site of
an accident, on the battlefield, in the accident and emergency department and
throughout the hospital. This device will provide vital information for doctors,
allowing them to make better informed decisions, more quickly, about how best to
treat their patients. The SupraQ has the potential to extend the use of Deltex
Medical's proprietary monitoring technology into every environment where
patients can benefit from early diagnosis of hypovolaemia.


                      This information is provided by RNS
            The company news service from the London Stock Exchange